Gut microbiota-derived metabolites are novel targets for improving insulin resistance

作     者：Rosana MC Bastos Érika B Rangel 

作者机构：Hospital Israelita Albert EinsteinSão Paulo 05652-001SPBrazil Nephrology DivisionFederal University of São PauloSão Paulo 04023-900SPBrazil 

出 版 物：《World Journal of Diabetes》 (世界糖尿病杂志（英文版）（电子版）)

年 卷 期：2022年第13卷第1期

页      面：65-69页

核心收录：

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

基　　金：Supported by São Paulo Research Foundation,No.2013/19560-6 and No.2017/23195-2 EFSD(European Foundation for the Study of Diabetes)/Sanofi(to RangelÉB) 

主　　题：Insulin resistance Gut microbiota Metabolites Host metabolism Metabolic organs Novel targets 

摘      要：The gut microbiota plays a key role in metabolic ***-microbiota-derived metabolites are found in different dietary sources,including:Carbohydrate(acetate,propionate,butyrate,also known as short-chain fatty acids,as well as succinate);protein(hydrogen sulfide,indole,and phenylacetic acid);and lipids(resveratrol-,ferulic acid-,linoleic acid-,catechin-and berry-derived metabolites).Insulin resistance,which is a global pandemic metabolic disease that progresses to type 2 diabetes mellitus,can be directly targeted by these ***-derived metabolites have broad effects locally and in distinct organs,in particular skeletal muscle,adipose tissue,and *** metabolites can modulate glucose metabolism,including the increase in glucose uptake and lipid oxidation in skeletal muscle,and decrease in lipogenesis and gluconeogenesis associated with lipid oxidation in the liver through activation of phosphatidylinositol 3-kinase-serine/threonine-protein kinase B and AMP-activated protein *** adipose tissue,gut-microbiota-derived metabolites stimulate adipogenesis and thermogenesis,inhibit lipolysis,and attenuate ***,an increase in energy expenditure and fat oxidation occurs in the whole ***,the therapeutic potential of current pharmacological and non-pharmacological approaches used to treat diabetes mellitus can be tested to target specific metabolites derived from intestinal bacteria,which may ultimately ameliorate the hyperglycemic burden.